Phase 3 N=1,025 Study of Milnacipran for the Treatment of Fibromyalgia
Fibromyalgia
Primary: Composite Syndrome Responder Status — 56; 103 Syndrome Responder Participants — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=306 An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))
Proteinuria
Primary: Double-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12 — -35.80; 1.37 Percent Change in Pr/Cr — p=0.001
Phase 3 N=547 A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee
Osteoarthritis · Chronic Pain
Primary: Mean Change From Randomization to 12 Weeks Following Randomization in Diary Brief Pain Inventory Score of Average Pain (Daily Scores of Average Pain Averaged Over 7…
Phase 3 N=3,070 Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)
Hepatitis C, Chronic
Primary: Sustained Virologic Response (SVR) Rate — 39.8; 38.0; 40.9 Percentage of participants — p=0.567
Phase 3 N=467 Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain
Pain
Primary: Subjects With Treatment Emergent Adverse Events — 378 participants
Phase 3 N=526 A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies
Seasonal Allergic Rhinitis
Primary: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo — 17.86; 18.29; 17.83; -2.36 total…
Phase 3 N=433 Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.
Haemophilus Influenzae Type b · Neisseria Meningitidis
Primary: Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL) — 292; 100…
Phase 3 N=641 Sitagliptin Added-on to Insulin Study (0431-051)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in A1C at Week 24 — -0.59; -0.03 Percent — p=<0.001
Phase 3 N=304 Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)
Crohn's Disease
Primary: Mean Extent of Exposure - Duration in Days — 159.2 days
Phase 3 N=20 Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma
Allergic Asthma
Primary: Change in Exhaled Nitric Oxide From Baseline to Week 12 — -11.0 parts per billion (ppb) — p=0.005
Phase 3 N=324 Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17
Attention Deficit Disorder With Hyperactivity
Primary: Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Score at 6 Weeks — -19.44; -18.09; -20.00; -20.57 Units on a Scale — p=0.0041
Phase 3 N=466 Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema
Dermatitis · Eczema
Primary: Responder Status According to Pruritus Severity Score (Response = Mild or None in Pruritus Severity Score). — 131; 134; 37; 38 Participants
Phase 3 N=69 Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months
Allergic Rhinitis · Chronic Urticaria
Primary: Change From Baseline at Visit 4 (Day 14) or at Early Discontinuation Visit (EDV) in Ventricular Rate (VR) — -7.6; -4.0 beats per minute
Phase 3 N=8,687 Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210)
Infections, Rotavirus
Primary: Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strains — 0; 13 subjects
Phase 3 N=1,478 Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)
Hepatitis B
Primary: Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of RECOMBIVAX HB in Infancy — 323; 305 Participants — p=<0.001